All In Biotech

Drug Trial Radar · NCT04576988

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

324

Actual

Start

Jan 25, 2021

Primary completion

Aug 26, 2022

Study completion Dec 6, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. The primary hypothesis of the study is that the participants receiving sotatercept will have improved 6-minute walk distance (6MWD) at 24 weeks compared to participants receiving placebo.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • SotaterceptBiological

    Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.

  • PlaceboDrug

    Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.

  • Background PAH TherapyDrug

    Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 24 weeks
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 24 weeks

Locations

120 sites in 21 countries. Site status is shown where the registry gives one.

  • Arizona Pulmonary Specialists (Site 1010)

    Phoenix, Arizona

  • Pulmonary Associates, PA (Site 1008)

    Phoenix, Arizona

  • University of Arizona (Site 1006)

    Tucson, Arizona

  • University of California San Diego Medical Center (Site 1002)

    San Diego, California

  • University of California - Davis Medical Center (Site 1064)

    Sherman Oaks, California

  • Stanford University Medical Center (Site 1024)

    Stanford, California

  • Harbor UCLA Medical Center (Site 1028)

    Torrance, California

  • University of Colorado Hospital (Site 1013)

    Aurora, Colorado

  • The George Washington University Medical Faculty Associates (Site 1025)

    Washington D.C., District of Columbia

  • Mayo Clinic Jacksonville (Site 1045)

    Jacksonville, Florida

  • University of South Florida (Site 1043)

    Tampa, Florida

  • The Emory Clinic (Site 1030)

    Atlanta, Georgia

  • Norton Pulmonary Specialists (Site 1066)

    Louisville, Kentucky

  • Tufts Medical Center - PPDS (Site 1012)

    Boston, Massachusetts

  • Brigham and Women's Hospital (Site 1014)

    Boston, Massachusetts

  • University of Michigan (Site 1011)

    Ann Arbor, Michigan

  • University of Minnesota (Site 1062)

    Minneapolis, Minnesota

  • Mayo Clinic (Site 1023)

    Rochester, Minnesota

  • University of Kansas Medical Center (Site 1020)

    Kansas City, Missouri

  • Washington University School of Medicine (Site 1022)

    St Louis, Missouri

  • Nebraska Medical Center (Site 1053)

    Omaha, Nebraska

  • Renown Institute for Heart & Vascular Health (Site 1055)

    Reno, Nevada

  • New York Presbyterian Hospital (Site 1046)

    New York, New York

  • Duke University Medical Center (Site 1026)

    Durham, North Carolina

  • University of Cincinnati Medical Center (Site 1035)

    Cincinnati, Ohio

  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital (Site 1001)

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center (Site 1005)

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center (Site 1032)

    Columbus, Ohio

  • Oregon Health and Science University (Site 1054)

    Portland, Oregon

  • University of Pennsylvania (Site 1047)

    Philadelphia, Pennsylvania

  • UPMC Presbyterian. UPMC Presbyterian Hospital (Site 1059)

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital (Site 1033)

    Providence, Rhode Island

  • Medical University of South Carolina - PPDS (Site 1003)

    Charleston, South Carolina

  • Statcare Pulmonary Consultants - Knoxville (Site 1031)

    Knoxville, Tennessee

  • Vanderbilt University Medical Center (Site 1027)

    Nashville, Tennessee

  • CHI St. Luke's Health Baylor College of Medicine Medical Center (Site 1044)

    Houston, Texas

  • Houston Methodist Hospital (Site 1009)

    Houston, Texas

  • University of Utah - PPDS (Site 1049)

    Salt Lake City, Utah

  • University of Washington Medical Center - Montlake (Site 1067)

    Seattle, Washington

  • Hospital Provincial Dr. Jose M. Cullen ( Site 1902)

    Santa Fe, Argentina

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.